Prof. Susan Clark This is Me

 View all 19 references Web References

1. 1. events.unimelb.edu.au

   events.unimelb.edu.au/event/47 - [Cached]

   Published on: 5/5/2008   Last Visited: 5/14/2008

   Dr Clark's group was responsible for developing the bisulphite sequencing protocol that was pioneered in Dr Marianne Frommer's lab in the early 1990s and this technique is now well established internationally as the best method to detect methylated cytosines in a DNA sequence.
   ...
   Speaker: Professor Susan Clark

2. 2. Today's News

   www.prnewswire.com/cgi-bin/sto - [Cached]

   Published on: 1/27/2003   Last Visited: 1/27/2003

   In addition, Epigenomics announced that Prof. Andrew Feinberg (M.D., M.P.H), Johns Hopkins University and Associate Prof. Susan Clark, (PhD), the Sydney Cancer Centre have joined the company's Scientific Advisory Board (SAB).
   ...
   With Susan and Andrew joining our SAB, the leadership of Epigenomics in the development of DNA-methylation based personalized medicines is supported and confirmed," Alexander Olek, CEO of Epigenomics, commented.
   ...
   Both Professors Clark and Feinberg are pioneers in the field of DNA methylation and have contributed significant research to the field.
   ...
   Associate Professor Susan Clark developed bisulfite sequencing, allowing researchers to detect methylation at any given cytosine in DNA. This has led to a better understanding of the dynamics of the methylation process and its role in development, genomic imprinting, gene expression, and cancer. Subsequently she discovered potentially useful diagnostic markers for the early detection of prostate cancer that could help the development of a blood-based prostate cancer screening test through a collaboration with scientists from CSIRO.

3. 3. Epigenomics Accesses Additional DNA Methylation Technologies for Early Detection of Tumors and Expands Its Scientific Advisory Board

   biz.yahoo.com/prnews/030127/ln - [Cached]

   Published on: 1/27/2003   Last Visited: 1/27/2003

   In addition, Epigenomics announced that Prof. Andrew Feinberg (M.D., M.P.H), Johns Hopkins University and Associate Prof. Susan Clark, (PhD), the Sydney Cancer Centre have joined the company's Scientific Advisory Board (SAB).
   ...
   With Susan and Andrew joining our SAB, the leadership of Epigenomics in the development of DNA-methylation based personalized medicines is supported and confirmed," Alexander Olek, CEO of Epigenomics, commented.
   ...
   Both Professors Clark and Feinberg are pioneers in the field of DNA methylation and have contributed significant research to the field.
   ...
   Associate Professor Susan Clark developed bisulfite sequencing, allowing researchers to detect methylation at any given cytosine in DNA. This has led to a better understanding of the dynamics of the methylation process and its role in development, genomic imprinting, gene expression, and cancer. Subsequently she discovered potentially useful diagnostic markers for the early detection of prostate cancer that could help the development of a blood-based prostate cancer screening test through a collaboration with scientists from CSIRO.